March 04, 2021
The FDA has accepted a New Drug Application for pafolacianine sodium injection and granted it Priority Review as a potential adjunct for identifying ovarian cancer during surgery.
February 23, 2021
A novel DNA-mediated interleukin-12 immunotherapy, GEN-1, had been granted a Fast Track designation by the FDA for the treatment of advanced ovarian cancer.
February 21, 2021
Gynecologic oncology relies on both historical and modern therapies for the treatment of patients with ovarian cancer. During a Targeted Oncology Case-Based Peer Perspective virtual event, Michael J. Birrer, MD, PhD, reviewed the data.
February 17, 2021
During a Targeted Oncology Case-Based Peer Perspective event, Kathleen Moore, MD, discussed the combination of bevacizumab and olaparib as treatment of ovarian cancer.
January 02, 2021
During a Targeted Oncology Case Based Peer Perspectives event, Bradley Monk, MD, discussed how the use of molecular testing can improve treatment decisions for ovarian cancer.
December 25, 2020
During a Targeted Oncology Case Based Peer Perspectives event, John K. Chan, MD, reviewed the case of a 49-year-old African American woman with high-grade epithelial ovarian cancer.
December 24, 2020
Thomas C. Krivak, MD, interpreted the results clinical trials of bevacizumab as treatment of patients with ovarian cancer to determine the optimal treatment strategy for a 69-year-old patient.
December 21, 2020
Treatment with rucaparib led to an improvement in investigator-assessed progression-free survival compared with chemotherapy in patients with relapsed ovarian cancer with a BRCA mutation who have received 2 or more prior lines of chemotherapy, meeting the primary end point of the phase 3 ARIEL4 clinical trial.
September 18, 2020
Patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who experienced complete or partial response following platinum-based chemotherapy continued to exhibit benefit in progression-free survival when receiving olaparib at long-term follow up versus placebo as first-line maintenance.
September 14, 2020
Binimetinib demonstrated activity as treatment of patients with low-grade serous ovarian carcinomas in the randomized phase 3 MILO/ENGOT-ov11 study.